All In Biotech

Free tool

FAERS Monitor: Thallous Chloride Tl 201

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018150 or its brand name (Thallous Chloride Tl 201, Thallous Chloride Tl-201). Reports on generic versions are filed under their own applications.

Reports

51

Serious

36

71% of reports

Hospitalization

8

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • tremor8
  • dizziness7
  • dyspnoea7
  • chills6
  • hyperhidrosis6
  • asthenia5
  • hepatitis b4
  • nausea4
  • blood pressure decreased3
  • bradycardia3
  • chest pain3
  • hypotension3
  • pyrexia3
  • rash3
  • cough2

Reports by year received

View as table
YearReports
20055
20071
20089
20141
20153
20161
20171
20186
20192
202021
20211

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,108 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis bSignal4273.9106.9832
bradycardiaSignal323.37.844
chillsSignal621.110.096
tremorSignal819.910.5126
hyperhidrosisSignal619.29.187
blood pressure decreasedSignal318.66.234
chest painSignal36.72.29
hypotensionSignal36.22.18
dizzinessSignal75.82.924
astheniaSignal55.52.414
dyspnoeaSignal75.12.620
pyrexia33.61.23
cough22.90.81
rash32.80.92
nausea42.10.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.